Neurogene (NGNE) Net Cash Flow (2013 - 2026)
Neurogene's (NGNE) quarterly Net Cash Flow came in at $20.3 million in Q1 2026, up 130.9% YoY from $8.8 million in Q1 2025, and down 38.0% on a QoQ basis from $32.8 million in Q4 2025.
Neurogene (NGNE) Net Cash Flow (2013 - 2026) Analysis & Trends
Neurogene (NGNE) has 14 years of Net Cash Flow data on file, last reported at $20.3 million in Q1 2026.
- Quarterly Net Cash Flow rose 130.9% year-over-year to $20.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53.4 million (up 167.29% YoY) and the FY2025 annual result came in at -$32.7 million, down 177.63% from the prior year.
- Net Cash Flow retreated to $20.3 million in Q1 2026, from $32.8 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $113.6 million in Q4 2022 to a low of -$65.8 million in Q1 2025.
- A 5-year average of $3.2 million and a median of -$11.9 million in 2025 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow jumped 1012.2% — and 2025, when it plunged 3837.37%.
- Tracing NGNE's Net Cash Flow over 5 years: stood at $113.6 million in 2022, then fell by 9.22% to $103.2 million in 2023, then plunged by 32.19% to $70.0 million in 2024, then sank by 53.12% to $32.8 million in 2025, then plunged by 38.0% to $20.3 million in 2026.
- The last three Net Cash Flow figures came in at $20.3 million (Q1 2026), $32.8 million (Q4 2025), and $12.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Neurogene | 815.03 Mn | 815.03 Mn | - | -11.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.70 Mn |
| Jun 30, 2026 | -11.70 Mn |
| Mar 31, 2026 | 20.34 Mn |
| Mar 31, 2026 | 20.34 Mn |
| Dec 31, 2025 | 32.80 Mn |
| Dec 31, 2025 | 32.80 Mn |
| Sep 30, 2025 | 12.20 Mn |
| Sep 30, 2025 | 12.20 Mn |
| Jun 30, 2025 | -11.92 Mn |
| Jun 30, 2025 | -11.92 Mn |
| Mar 31, 2025 | -65.82 Mn |
| Mar 31, 2025 | -65.82 Mn |
| Dec 31, 2024 | 69.95 Mn |
| Dec 31, 2024 | 69.95 Mn |
| Sep 30, 2024 | -44.40 Mn |
| Sep 30, 2024 | -44.40 Mn |
| Jun 30, 2024 | -39.11 Mn |
| Jun 30, 2024 | -39.11 Mn |
| Mar 31, 2024 | 1.76 Mn |
| Mar 31, 2024 | 1.76 Mn |